Recombinant factor VIIa (NovoSeven RT) use in high risk cardiac surgery.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  European Journal of Cardio-Thoracic Surgery

• Publication date

  2011-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ejcts.2011.03.048PMID 21601468
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Administration of recombinant activated factor VII in the intensive care unit after complex cardiovascular surgery: clinical and economic outcomes.

  2011cited by this paper
• The impact of blood conservation on outcomes in cardiac surgery: is it safe and effective?

  2010cited by this paper
• Predictors of prolonged mechanical ventilation in a cohort of 5123 cardiac surgical patients

  2009cited by this paper
• Efficacy and safety of activated recombinant factor VII in cardiac surgical patients

  2009cited by this paper
• Costs of excessive postoperative hemorrhage in cardiac surgery.

  2009cited by this paper
• Comprehensive Canadian Review of the Off-Label Use of Recombinant Activated Factor VII in Cardiac Surgery

  2008cited by this paper
• Recombinant activated factor VII in cardiac surgery: experience from the Australian and New Zealand Haemostasis Registry.

  2008influential reference
• The role of recombinant factor VIIa in on-pump cardiac surgery: Proceedings of the Canadian Consensus Conference

  2007influential reference
• Recombinant activated factor VII in cardiac surgery: a systematic review.

  2007cited by this paper
• Successful use of activated recombinant factor VII in life threatening bleeding after thoracic surgery.

  2007cited by this paper
• Recombinant activated factor VII in the management of life-threatening bleeding in cardiac surgery.

  2005cited by this paper
• Safety profile of recombinant factor VIIa.

  2004cited by this paper
• The incidence and risk of acute renal failure after cardiac surgery.

  2004cited by this paper
• Effect of blood transfusion on long-term survival after cardiac operation.

  2002cited by this paper
• Reexploration for Hemorrhage Following Coronary Artery Bypass GraftingIncidence and Risk Factors

  2000cited by this paper
• Eurp-pean system for cardiac operative risk evaluation (Euro SCORE)

  1999cited by this paper
• European system for cardiac operative risk evaluation (EuroSCORE).

  1999cited by this paper
• The Epidemiology of Hemorrhage Related to Cardiothoracic Operations

  1998cited by this paper
• Reexploration for hemorrhage following coronary artery bypass grafting: incidence and risk factors. Northern New England Cardiovascular Disease Study Group.

  1998cited by this paper
• Hemorrhage and the use of blood products after adult cardiac operations: myths and realities.

  1996cited by this paper
• Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations.

  1996cited by this paper
• Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors.

  1983cited by this paper

• Comparison of Prothrombin Complex Concentrate with Activated Factor VII Use for Bleeding Following Cardiopulmonary Bypass in Children

  2023cites this paper
• Factor eight inhibiting bypass activity for refractory bleeding in acute type A aortic dissection repair: A propensity‐matched analysis

  2022cites this paper
• Alternative Factor Prescribing after Low-Dose Recombinant Factor VIIa Protocol in Cardiac Surgery

  2022cites this paper
• The Use of Factor Eight Inhibitor Bypass Activity (FEIBA) for the Treatment of Perioperative Hemorrhage in Left Ventricular Assist Device Implantation.

  2021cites this paper
• Hemostatic Agents and Blood Components Used to Stop Bleeding

  2021cites this paper
• Recombinant activated factor VII for hemostasis in patients undergoing complex ascending aortic surgery: A single‐center, single‐surgeon retrospective analysis

  2021cites this paper
• What's New in Cardiopulmonary Bypass.

  2019cites this paper
• A Propensity-Score Matched Analysis on Outcomes Using Recombinant Activated Factor VII in Pediatric Cardiac Surgery.

  2019cites this paper
• Characteristics Associated With Mortality in 372 Patients Receiving Low-Dose Recombinant Factor VIIa (rFVIIa) for Cardiac Surgical Bleeding.

  2019cites this paper
• A role for very low‐dose recombinant activated factor VII in refractory bleeding after cardiac surgery: Lessons from an observational study

  2018cites this paper
• Recombinant activated factor VII is associated with postoperative thromboembolic adverse events in bleeding after coronary surgery.

  2018cites this paper
• Outcomes Following Three-Factor Inactive Prothrombin Complex Concentrate Versus Recombinant Activated Factor VII Administration During Cardiac Surgery.

  2018cites this paper
• Take me to your bleeder: Recombinant factor VIIa-finding its way in cardiac surgery.

  2017cites this paper
• Change of coagulation after NovoSeven® use for bleeding during cardiac surgery

  2017cites this paper
• Perioperative Use of Coagulation Factor Concentrates in Patients Undergoing Cardiac Surgery.

  2017cites this paper
• [Activated Factor VII - 31 years experience on clinical grounds].

  2017cites this paper
• Hemostatic Agents Used to Stop Bleeding

  2016cites this paper
• Analysis of Outcomes Using Low-Dose and Early Administration of Recombinant Activated Factor VII in Cardiac Surgery.

  2016cites this paper
• Massive bleeding in cardiac surgery. Definitions, predictors and challenges.

  2016cites this paper
• Bleeding Related to Cardiac Surgery

  2016cites this paper
• Comparison of low- and high-dose recombinant activated factor VII for postcardiac surgical bleeding

  2016cites this paper
• The Effect of Intravenous Administration of Active Recombinant Factor VII on Postoperative Bleeding in Cardiac Valve Reoperations; A Randomized Clinical Trial

  2015cites this paper
• Predicting excess bleeding due to haemostatic failure following cardiac surgery requiring cardiopulmonary bypass

  2015influential citation
• Correcting thrombin generation ex vivo using different haemostatic agents following cardiac surgery requiring the use of cardiopulmonary bypass

  2015cites this paper
• Recombinant Activated Factor VII Significantly Reduces Transfusion Requirements in Cardiothoracic Surgery

  2015cites this paper
• Recombinant factor VII is associated with worse survival in complex cardiac surgical patients.

  2014cites this paper
• Safety and efficacy of recombinant activated factor VII for refractory hemorrhage in pediatric patients on extracorporeal membrane oxygenation: a single center review

  2014cites this paper
• Herz- und thorakale Gefäßchirurgie – Gerinnungsstörungen: klinische Grundlagen und mechanismenbasierte Therapie

  2014cites this paper
• [Off-label use of recombinant factor VII (rFVIIa) in teaching hospitals in Paris in 2010].

  2013cites this paper
• Utilisation hors AMM du facteur VII activé recombinant (Novoseven®) à l’AP–HP en 2010

  2013cites this paper
• Recombinant factor VIIa while on extracorporeal membrane oxygenator support: a word of caution.

  2012influential citation
• Hemocoagulative Aspects of Solid Organ Transplantation

  2012cites this paper
• No evidence or no alternative? Taking responsibility for off‐label prescribing

  2012cites this paper
• The causes of re-operation in the Ross procedure.

  2012influential citation
• Can we implant valved mitral prosthesis within all kinds of mitral rings through a transapical approach?

  2012cites this paper
• Haemostatic management in high-risk cardiac surgery: a role of recombinant factor VIIa (NovoSeven RT).

  2012cites this paper
• Review of the Off-Label Use of Recombinant Activated Factor VII in Pediatric Cardiac Surgery Patients

  2012cites this paper
• Intraoperative use of low-dose recombinant activated factor VII during thoracic aortic operations.

  2012cites this paper
• Unauthorized reproduc Anesthetic considerations for interventional pulmonary procedures

  2012cites this paper
• Cervical cancer screening (November 2011)

  2012cites this paper
• Use of recombinant factor VII in cardiac surgery.

  2012cites this paper
• Hemostatic management in complex aortic surgery: a role for multiple electrode aggregometry and modified rotational thromboelastometry.

  2012cites this paper
• Another argument for values-based medicine

  2011cites this paper
• Dabigatran (October 2011)

  2011cites this paper
• The perils of proxy outcomes in evidence-based medicice: the case of recombinant Factor VIIa

  2011cites this paper